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Methylprednisolone is a corticosteroid medication used in acute traumatic spinal cord injury
(SCI) to tackle secondary injury cascades. Its use in acute SCI has been the subject of controversy
for over 30 years. The second National Acute Spinal Cord Injury Study (NASCIS-2) demon-
strated a small benefit of methylprednisolone,1 though this conclusion was derived from a post
hoc subgroup analysis.2 Studies that followed did not reach the same conclusion and reported
potential adverse effects of the drug.3 However, the 2017 AOSpine guideline continues to
recommend high-dose methylprednisolone within 8 hours postinjury,4 based on a meta-analysis
with rigid inclusion criteria.5This Journal Club article reports on a study fromLiu et al.,6who have
attempted to resolve this controversy. The study provides an elegant example of meta-analytic
methods and has important implications for neurologic clinical practice.
Hypotheses and design
Does acutely administered methylprednisolone improve neurologic recovery following trau-
matic SCI? To answer this important question, Liu et al.6 performed a meta-analysis of clinical
trials and observational studies. The use of a meta-analysis is important here as it synthesizes all
available evidence and provides the highest possible strength of recommendation for its use in
clinical management.
Methods
This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines, which is an evidence-based minimum set of items for reporting in
systematic reviews and meta-analyses.7 A comprehensive literature search was performed of
PubMed and the Cochrane Library, and articles were further restricted to those published in
journals included in the Science Citation Index. In addition to traditional database searches, manual
searches of the reference lists of all of the relevant studies, review articles, and conference abstracts
were also conducted. Searching multiple databases is recommended when conducting meta-
analyses in order to identify all the relevant articles. For instance, the Cochrane Handbook suggests
the use of MEDLINE (accessible through PubMed) and the Cochrane Central Register of Con-
trolled Trials.8 Other commonly used databases include the Web of Science and Google Scholar.9
The review included studies in which participants were diagnosed with traumatic SCI. Methyl-
prednisolone intervention was initiated within 8 hours after injury (based on prior evidence that
patients treated after 8 hours postinjury recovered less motor function compared with placebo).10
Studies with a drug-naive control group were included. Other inclusion criteria for studies included
reporting of neurologic outcomes, adverse events, or in-hospital costs. Two blinded reviewers
evaluated articles identified in the initial search to reduce the risk of bias. From each article, the
following data were then extracted: demographics, sample size, percent of patients with complete
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injuries, percent of patients who received surgeries, length of
follow-up, and outcomes (neurologic scores, adverse events, in-
hospital costs). For randomized trials, quality was assessed with
a risk of bias assessment according to the Cochrane Handbook
for Systematic Reviews and Interventions.8This tool includes an
assessment of various biases including selection bias, attrition
bias, detection bias, performance bias, and reporting bias. For
observational studies, quality was assessed using the Newcastle-
Ottawa Scale (NOS).11 For the NOS, each study is judged on 3
broad categories: selection of study groups, comparability of
study groups, and ascertainment of exposures and outcomes.
The NOS ranges from 0 to 9 points; studies that score at least 6
are considered high quality (i.e., low risk of bias).
The outcomes were pooled using random-effects and fixed-
effects meta-analyses. In a fixed-effects meta-analysis, we assume
that each of the studies included are estimating the same treat-
ment effect (true value). Therefore, the different effect estimates
(from the different studies) are attributed purely to random
sampling error.12 However, in most settings, this assumption
does not hold: studies may have different inclusion criteria,
treatments may have been administered by different protocols,
and outcomes may have been captured differently. To account
for these between-study differences (heterogeneity), random-
effects meta-analysis is used.12 Heterogeneity was assessed with
I2 statistics, which describe the percentage of variation across
studies that is due to heterogeneity rather than chance, and
a 95% confidence interval (CI) can be constructed for I2.8
Continuous variables were summarized with pooled mean dif-
ferences and 95% CIs. Dichotomous variables were summarized
with pooled risk ratios and 95%CIs. In either case, the 95%CI can
be interpreted as the certainty (confidence) that the true measure
lies within the given range.8 Subgroup analyses were performed,
one stratifying by study design (observational vs randomized trial)
and by duration of follow-up (≤2 months or >2 months).
Results
The broad electronic search strategy yielded 1,574 articles, and
of these, 16 studies were included in the final analysis (3 ran-
domized controlled trials and 13 observational studies). The
quality assessment revealed that the observational studies and
the randomized controlled trials were of modest or low risk of
bias. The random-effects meta-analysis (graphically illustrated
in the forest plot) did not detect a significant difference be-
tween the methylprednisolone and control groups for the
pooled motor and sensory scores at last follow-up. This lack of
difference was independent of study design and duration of
follow-up. The corticosteroid was associated with a significantly
higher incidence of adverse events, which included gastroin-
testinal hemorrhage and respiratory tract infection.
Interpretation
Liu et al.6 have brought to attention the use of methylpred-
nisolone in acute traumatic SCI and concluded that high-dose
methylprednisolone does not improve neurologic outcomes
in acute traumatic SCI and may increase the risk of adverse
events. They recommend against the use of this corticosteroid
early after injury.
Study strengths and limitations
There are several strengths of this study and a few potential
limitations related to its design, presentation of results, and
research question. First, the authors formulated a focused
research question, which can minimize heterogeneity be-
tween studies and aid in the identification and selection of
studies.
Second, this is the largest meta-analysis of acute methyl-
prednisolone to date, consisting of 3 clinical trials and 13
observational studies. This is particularly impressive given
that SCI is considered an orphan condition.13 The included
studies were restricted to English-language articles, though
language-restricted meta-analyses tend to overestimate
treatment effects by 2% on average.14
Third, articles were reviewed and data were extracted by 2
blinded reviewers, which reduces bias and reduces the likeli-
hood of data entry errors.
Fourth, the results of the study were presented in accordance
with PRISMA guidelines,7 including the use of clear forest
plots (the graphical display of results from individual studies
and the overall pooled result) and a clearly presented flow
diagram of studies included in the final analysis.
Individual participant data, which were not used in this meta-
analysis, have several advantages, including that overlapping
sets of participants can be identified, and adjusted estimates
can be produced where previously only unadjusted estimates
were available.15 However, obtaining individual data is often
not feasible as it requires contacting the authors of the original
studies, and is particularly challenging for older studies.
With regards to the analysis, another major strength of the
meta-analysis was the use of stratification by study design and
duration of follow-up. Other potential stratifications could
have included stratification by lesion level, particularly for
adverse events (e.g., more respiratory complications in tet-
raplegia), and stratification by intention to treat vs per pro-
tocol. With regards to bias, the relationship between
methylprednisolone use and neurologic outcomes could be
confounded by other factors not included in the analyses,
including surgical intervention, blood pressure maintenance,
premorbid disability, and mechanism of injury. Confounding
occurs when the true association between an exposure and an
outcome is distorted by the presence of another variable
(i.e., the confounder).16
Another strength of the Liu et al.6 meta-analysis was that an
assessment of study quality was performed, although the
quality score was not used in the meta-analysis. There are
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several techniques for incorporating quality scores in meta-
analyses, including excluding studies of a certain quality,
subgroup analyses by study quality, and incorporating quality
scores as weights in the meta-analysis.17
Finally, the meta-analysis included studies with a range of ages
and both complete and incomplete injuries, which increases
the generalizability of this study.
Overall, despite the study limitations, this study is relevant to
neurologic practice. Indeed, this study is the most compre-
hensive synthesis of the relevant literature to date. This in
combination with the other major strengths of this study
make it an important contribution to neurologic practice.
Study funding
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